US FDA issue 8 observations to Sun Pharma’s Halol plant after Recent Inspection
Sun Pharma’s Halol plant production facility in Gujarat has come under renewed scrutiny from the US Food and Drug Administration (US FDA). FDA issued 8 observations after current inspection. According to a regulatory filing by agecy, US FDA conducted a Good Manufacturing Practices (GMP) inspection at the Halol site from June 2 to June 13,